Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Monoprost versus Lumigan in glaucoma or ocular hypertension with ocular surface intolerance
2013-001250-10Phase 4Completed
- Sponsor
- Laboratoires Théa
- Start
- Jul 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of latanoprost and bimatoprost in open-angle glaucoma (OAG) and ocular hypertension (3 arms), sponsored by Laboratoires Théa. Primary endpoint: Change from baseline in conjunctival hyperaemia at Day 84. Started Jul 2013; status: completed.
02
Drugs
latanoprostbimatoprost
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on 2013-001250-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001250-10.